ProShares Ultra NASDAQ Biotechnology
17 hedge funds and large institutions have $1.62M invested in ProShares Ultra NASDAQ Biotechnology in 2025 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 7 closing their positions.
4.02% less ownership
Funds ownership: 7.5% → 3.47% (-4%)
26% less funds holding
Funds holding: 23 → 17 (-6)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
60% less capital invested
Capital invested by funds: $4.04M → $1.62M (-$2.42M)
86% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$30.6K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$5.42K |
| 3 |
Morgan Stanley
New York
|
+$969 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IMC Chicago
Chicago,
Illinois
|
-$1.08M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$519K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$332K |
| 4 |
TFA
Toth Financial Advisory
Leesburg,
Virginia
|
-$204K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$80.8K |
BIB Hedge Fund Activity: Q2 2025 in Review
17 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in ProShares Ultra NASDAQ Biotechnology (BIB) for Q2 2025, worth a combined $1.62M — down 60% from $4.04M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of BIB and 1 opened new positions — a net loss of 6 holders — while 4 trimmed existing stakes and 2 added.
The largest buyer was Franklin Resources, opening a new position worth an estimated $30.6K. The largest seller was IMC Chicago, exiting entirely with an estimated $1.08M sold.
- 17 institutional investors held ProShares Ultra NASDAQ Biotechnology (BIB) as of Q2 2025, down from 23 in Q1 2025.
- Funds reported $1.62M of ProShares Ultra NASDAQ Biotechnology stock for Q2 2025, down 60% quarter-over-quarter.
- 1 fund opened new ProShares Ultra NASDAQ Biotechnology positions in Q2 2025 and 7 closed out, a net change of -6 holders.
- The largest ProShares Ultra NASDAQ Biotechnology buyer in Q2 2025 was Franklin Resources, an estimated $30.6K added.
- The largest ProShares Ultra NASDAQ Biotechnology seller in Q2 2025 was IMC Chicago, an estimated $1.08M sold.
Based on aggregated 13F filings for Q2 2025.